Oren Josh Becher

This study identifies a combinatorial strategy using ALK2 inhibitors and statins to target metabolic dependencies in diffuse midline glioma.

This study identifies ADAR as a key mediator of immune evasion in H3K27M+ pediatric gliomas and shows that ATRA can induce ADAR degradation, enhancing antiviral responses and tumor immunogenicity.

This study evaluates combination therapy of CDK4/6 and MEK inhibitors in DMG models, finding survival benefits in GEM but not PDX models.

This study identifies CD155 as a key regulator of tumor growth and immune evasion in diffuse midline glioma, showing that targeting CD155 or its downstream target FOXM1 can inhibit tumor progression.

This study shows that disrupting ATM enhances radiation therapy efficacy in p53-mutant DMGs but not p53-wildtype DMGs using mouse models.